ロード中...
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
BACKGROUND: Response criteria developed when cytotoxic chemotherapy was the predominant therapeutic modality to treat patients with cancer, do not capture the full spectrum of tumor response patterns observed with anti-PD-1/PD-L1 antibody treatment. iRECIST was developed to capture both typical and...
保存先:
| 出版年: | J Immunother Cancer |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7057528/ https://ncbi.nlm.nih.gov/pubmed/32107275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000146 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|